Understanding the SPG89 Diagnosis
At a Glance
SPG89 is an ultra-rare autosomal recessive condition caused by AMFR gene mutations. It mainly causes progressive leg stiffness and weakness; some children also have developmental, speech, or cognitive differences, so care is tailored and supportive.
Receiving a diagnosis of SPG89 often brings a mix of relief that the “diagnostic odyssey”—the long process of ruling out other conditions before finding an answer—is over and profound uncertainty about what the future holds. This condition is an ultra-rare form of Hereditary Spastic Paraplegia (HSP), a group of genetic disorders that cause progressive stiffness and weakness in the legs [1]. Because SPG89 was only recently identified—with the primary research defining it published as recently as 2023—your child is known to have a condition with only a small number of reported cases worldwide [2].
It is completely normal if your local pediatrician or even your general neurologist has never heard of SPG89. In the medical literature, a very limited number of families have been documented globally [2][3]. You are essentially becoming an expert alongside your child’s care team.
What is SPG89?
SPG89 is caused by mutations in the AMFR gene [2]. This gene provides instructions for making a protein that helps manage lipids (fats) and maintain the structure of the endoplasmic reticulum, a vital part of the cell that acts like a manufacturing and packaging plant [2].
When this gene doesn’t work correctly, the long nerves that send signals from the brain to the leg muscles (the corticospinal tracts) begin to struggle. Based on cellular models, researchers hypothesize that these nerves are some of the longest in the body, making them particularly sensitive to the cellular “packaging” issues caused by AMFR mutations [2][1]. This results in:
- Spasticity: A medical term for muscle stiffness or tightness that can make movements jerky or difficult [4].
- Weakness: Specifically in the lower limbs, which may progress slowly over time [2].
- Autosomal Recessive Inheritance: In most cases of SPG89, a child must inherit two copies of the mutated gene—one from each parent—to develop the condition [2]. Genetic counseling is important for families: parents who are confirmed carriers typically have a 25% recurrence risk in each pregnancy of having another child with SPG89.
Impact on Mobility and Development
The primary impact of SPG89 is on how a child moves. While every child is different, the condition typically presents as progressive spastic paraplegia, meaning the stiffness in the legs may become more pronounced as the child grows [2].
- Gait Changes: Parents often first notice “toe-walking,” a stiff-legged gait, or frequent tripping [1].
- Developmental Milestones: Some children with SPG89 experience global developmental delay, which means they may reach milestones like sitting, crawling, or speaking later than their peers [2].
- Cognitive Impact: In some “complex” cases of SPG89, mild intellectual disability or speech impairments have been reported [2][1]. However, others may have a “pure” clinical presentation where the symptoms are almost entirely limited to leg stiffness [2]. Note that intellectual disability is not inevitable, and the exact cognitive profile varies per child.
Navigating an Ultra-Rare Diagnosis
Living with a diagnosis that has no “standard roadmap” is an immense emotional challenge. Because there are so few cases, doctors cannot always predict exactly how the condition will progress for an individual child [5].
Management currently focuses on symptomatic care, which means treating the symptoms your child has rather than the genetic cause itself [4]. This often includes:
- Physical Therapy: Aimed at maintaining flexibility and muscle strength based on functional goals [4][6].
- Occupational Therapy: Helping children adapt their daily activities and use any necessary tools or assistive devices [4].
- Spasticity Management: Using medications or other interventions to help relax tight muscles and improve comfort [4][7].
While the rarity of SPG89 means there is much still to learn, research is ongoing. Scientists are already using patient cells to study how AMFR mutations affect the body, which is the first step toward developing future treatments [2]. For now, your child’s care team will focus on supporting their unique developmental path and ensuring they have the tools they need to navigate the world.
Common questions in this guide
What gene causes SPG89?
How is SPG89 inherited, and what is the chance of having another affected child?
What movement problems can children with SPG89 develop?
Does SPG89 always cause developmental or intellectual disability?
How is SPG89 treated?
Can doctors predict exactly how SPG89 will progress?
Get notified when new evidence is published on spastic paraplegia 89, autosomal recessive.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (7)
- 1
Childhood-onset hereditary spastic paraplegia: at the crossroads between neurodevelopment and neurodegeneration.
Espasandin-Hueter N, Salazar-Villacorta A, Escudero JM, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2026; (65()):50-65 doi:10.1016/j.ejpn.2026.10.002.
PMID: 42976539 - 2
AMFR dysfunction causes autosomal recessive spastic paraplegia in human that is amenable to statin treatment in a preclinical model.
Deng R, Medico-Salsench E, Nikoncuk A, et al.
Acta neuropathologica 2023; (146(2)):353-368 doi:10.1007/s00401-023-02579-9.
PMID: 37119330 - 3
Experience in the clinical and genetic diagnosis of a series of Algerian patients with hereditary spastic paraplegias.
Messaoud-Khelifi M, Boulariah-Hadjou R, Kediha MI, et al.
Neurogenetics 2025; (26(1)):52 doi:10.1007/s10048-025-00833-8.
PMID: 40560206 - 4
French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.
Mania-Pâris L, Ewenczyk C, Nicolas G, et al.
Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.
PMID: 40450402 - 5
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review.
Siow SF, Yeow D, Rudaks LI, et al.
Genes 2023; (14(9)) doi:10.3390/genes14091756.
PMID: 37761896 - 6
The therapeutic effects of physical treatment for patients with hereditary spastic paraplegia: a narrative review.
Di Ludovico A, Ciarelli F, La Bella S, et al.
Frontiers in neurology 2023; (14()):1292527 doi:10.3389/fneur.2023.1292527.
PMID: 38093754 - 7
Rehabilitation management of children with hereditary spastic paraplegia: a retrospective cohort study.
Paget SP, McIntyre S, Lewis J, et al.
Developmental neurorehabilitation 2026; 1-8 doi:10.1080/17518423.2026.2738682.
PMID: 42831377
This page explains SPG89, its inheritance, and supportive care for educational purposes only; it does not replace medical advice. A pediatric neurologist and genetic counselor can interpret your child's results and plan care.